At the start of 2006, it looked like Pfizer Inc. might have a big headache in positioning pregabalin (Lyrica) under the newly implemented Medicare Part D drug benefit. The epilepsy drug is one of Pfizer’s most important new products, but when formulary information for Part D was first made public, Lyrica was nowhere to be found. In other words, Pfizer faced the prospect of missing out on a lucrative new prescription drug market.
Lyrica’s coverage profile was something the Epilepsy Foundation noticed as well. The organization had been very involved in the planning...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?